PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pacira BioSciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$36.34+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.46B
- P/E (TTM)
- 103.8
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
79.4%+6.7 pts over 5 years
Operating margin
2.6%−8.1 pts over 5 years
Net margin
1.0%−32.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +3.6% | +2.9% | +11.1% | +11.3% | |
| Gross profit | +8.7% | +7.2% | +13.0% | +12.5% | |
| Operating income | – | -31.6% | -16.2% | +7.3% | |
| Net income | – | -23.8% | -45.4% | +14.3% | |
| EPS, diluted | – | -22.2% | -45.5% | +14.9% | |
| Free cash flow | -23.5% | +5.9% | +28.4% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -17.4% | 29.9% | 1.0% | |
| Return on assets | -9.7% | 13.8% | 0.5% | |
| Current ratio | 5.42 | 2.57 | 4.54 | |
| Debt to equity | – | – | 0.54 | |
| Net debt to EBITDA | – | – | 1.94× | |
| Interest coverage | -4.5× | 1.8× | 1.1× | |
| Inventory turnover | 2.4× | 1.9× | 1.1× | |
| Capex to revenue | 8.9% | 8.8% | 2.1% | |
| Diluted shares | 37M | 44M | 45M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Pacira BioSciences generated $767.02M from operations and spent $290.40M on capital expenditure, dividends and share buybacks. 40% of that went back into the business.
Generated
$767.02M
Used
$290.40M
Capital expenditure$117.07M40%Dividends$00%Share buybacks$173.33M60%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin1.0%
×Asset turnover0.52×
×Equity multiplier1.92×
=Return on equity, FY20251.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 1.0% | 0.52× | 1.92× | 1.0% |
| FY2024 | -14.2% | 0.45× | 1.90× | -12.1% |
| FY2023 | 6.2% | 0.41× | 1.98× | 5.1% |
| FY2022 | 2.4% | 0.36× | 2.50× | 2.1% |
| FY2021 | 7.8% | 0.32× | 2.48× | 6.2% |
| FY2020 | 33.9% | 0.41× | 2.16× | 29.9% |
| FY2019 | -2.6% | 0.55× | 2.25× | -3.3% |
| FY2018 | -0.1% | 0.51× | 2.19× | -0.2% |
| FY2017 | -14.9% | 0.56× | 2.05× | -17.1% |
| FY2016 | -13.7% | 0.71× | 1.78× | -17.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
8of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$7.03M
- Cash generatingOperating cash flow above zero$151.99M
- Return on assets improvedROA up on the prior year-6.3% → 0.5%
- Earnings backed by cashOperating cash flow above net income$151.99M vs $7.03M
- Less leverageLong-term debt to assets fell24.7% → 29.4%
- Better liquidityCurrent ratio rose2.40 → 4.54
- No dilutionShare count did not rise46M → 45M
- Gross margin improvedGross margin up on the prior year75.69% → 79.39%
- More efficientAsset turnover rose0.45 → 0.47